Breaking News Instant updates and real-time market news.

TEVA

Teva

$19.13

0.02 (0.10%)

, MYL

Mylan

$43.14

0.03 (0.07%)

05:06
01/04/18
01/04
05:06
01/04/18
05:06

Teva upgraded to Buy from Neutral at Citi

Citi analyst Liav Abraham upgraded Teva Pharmaceutical to Buy and raised her price target for the shares to $24 from $16. The drugmaker closed yesterday up 2c to $19.13. The analyst "more constructive" on the Specialty Pharma group heading into 2018. More realistic expectations, along with pipeline catalysts set the stage for a potential inflection point for some of the stocks in 2018, Abraham tells investors in a research note on the sector. She believes Teva's risk/reward profile that is skewed to the upside over the near to medium as management executes on the recently announced cost cuts. Mylan (MYL) is Abraham's top pick for 2018.

TEVA

Teva

$19.13

0.02 (0.10%)

MYL

Mylan

$43.14

0.03 (0.07%)

  • 04

    Jan

  • 06

    Jan

  • 08

    Jan

  • 16

    Feb

TEVA Teva
$19.13

0.02 (0.10%)

12/15/17
DBAB
12/15/17
NO CHANGE
Target $20
DBAB
Hold
Teva price target raised to $20 from $14 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raised his price target for Teva Pharmaceutical to $20 to reflect greater cost reductions under the company's restructuring plan, partially offset by more conservative estimates for generics. The analyst keeps a Hold rating on the shares.
12/18/17
UBSW
12/18/17
NO CHANGE
Target $20
UBSW
Neutral
Teva price target raised to $20 from $12 at UBS
UBS analyst Marc Goodman raised his price target on Teva to $20 from $12 driven largely by the larger than expected $3B in cost reductions that improves its operating income and EBITDA. He notes, however, the restructuring will lower revenues, though he has adjusted for that as well. Goodman maintains his Neutral rating on Teva shares.
12/22/17
CANT
12/22/17
NO CHANGE
CANT
Cantor ups price targets for Teva, Valeant, Mylan, Zoetis
Cantor Fitzgerald analyst Louise Chen raised her price target for Neutral-rated Teva (TEVA) to $18 from $10, for Overweight-rated Valeant (VRX) to $25 from $23, for Neutral-Mylan (MYL) to $41 from $34 and for Overweight-rated Zoetis (ZTS) to $85 from $80. Heading into 2018, the analyst believes Perrigo (PRGO) has the best setup in the Specialty Pharmaceuticals space. The company has given the most visibility on its outlook for 2018, Chen tells investors in a research note. She believes Zoetis, Mylan and Horizon Pharma (HZNP) also look good into next year.
01/02/18
LEER
01/02/18
INITIATION
Target $15
LEER
Underperform
Teva initiated with an Underperform at Leerink
Leerink analyst Ami Fadia initiated Teva with an Underperform and $15 price target saying she is concerned on the sustainability of the top line and sees downside to consensus estimates, and expects debt load to continue to pressure shares.
MYL Mylan
$43.14

0.03 (0.07%)

12/12/17
12/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL), Teva (TEVA) and Endo (ENDP) initiated with a Neutral at Gugenheim, while Impax (IPXL) was initiated with a Buy. 2. Stitch Fix (SFIX) initiated with an Outperform at William Blair, a Neutral at JPMorgan and Goldman Sachs, an Overweight at Piper Jaffray, an Equal Weight at Barclays and a Hold at Stifel. 3. Exxon Mobil (XOM) and ConocoPhillips (COP) initiated with a Neutral at Credit Suisse. The firm also started Range Resources (RRC) and Anadarko (APC) with an Outperform, and Laredo Petroleum (LPI), Energen (EGN), Southwestern Energy (SWN), Noble Energy (NBL), Murphy Oil (MUR), Cabot Oil & Gas (COG) and Newfield Exploration (NFX) with a Neutral rating. 4. Restaurant Brands (QSR) initiated with an Outperform at Evercore ISI. 5. Waste Connections (WCN) initiated with an Outperform, named a top pick at BMO Capital. This list is just a portion of The Fly's full analyst coverage. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
LEHM
12/19/17
NO CHANGE
Target $40
LEHM
Overweight
Revance price target raised to $40 from $31 at Barclays
Barclays analyst Douglas Tsao raised his price target for Revance Therapeutics (RVNC) to $40 while detailing his 2018 outlook for the U.S. Specialty Pharmaceuticals sector. The analyst keeps an Overweight rating on the shares. Mylan (MYL) is Tsao's top pick for 2018.
01/02/18
LEER
01/02/18
INITIATION
Target $44
LEER
Market Perform
Mylan initiated with a Market Perform at Leerink
Leerink analyst Ami Fadia initiated Mylan with a Market Perform and $44 price target.

TODAY'S FREE FLY STORIES

BECN

Beacon Roofing

$32.97

4.9 (17.46%)

11:32
11/21/18
11/21
11:32
11/21/18
11:32
Upgrade
Beacon Roofing rating change  »

Beacon Roofing upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PCG

PG&E

$24.20

0.64 (2.72%)

11:30
11/21/18
11/21
11:30
11/21/18
11:30
Options
2K PG&E Mar 28 - 33 call spreads bought for $1.58 »

2K PG&E Mar 28 - 33…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
11/21/18
11/21
11:25
11/21/18
11:25
General news
Treasury's 10-year TIPS preview: the $11 B reopening may be weakened »

Treasury's 10-year…

AMD

AMD

$19.24

0.04 (0.21%)

11:20
11/21/18
11/21
11:20
11/21/18
11:20
Options
Sweep buyers of AMD weekly puts »

Sweep buyers of AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 06

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/21/18
11/21
11:17
11/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/21/18
11/21
11:16
11/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYAD

Celyad

$26.97

(0.00%)

, BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

11:11
11/21/18
11/21
11:11
11/21/18
11:11
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

CYAD

Celyad

$26.97

(0.00%)

BLUE

Bluebird Bio

$116.82

0.55 (0.47%)

NVS

Novartis

$88.49

1.51 (1.74%)

GILD

Gilead

$67.04

-0.54 (-0.80%)

CELG

Celgene

$67.69

0.93 (1.39%)

AUTL

Autolus Therapeutics

$42.60

1.4 (3.40%)

ALLO

Allogene Therapeutics

$26.40

0.79 (3.08%)

CLLS

Cellectis

$20.89

0.65 (3.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 27

    Nov

  • 29

    Nov

  • 01

    Dec

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 10

    Dec

  • 13

    Dec

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement CUSIP Number data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr FRN Note Announcement Offering Amount data reported »

2-Yr FRN Note…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
5-Yr Note Announcement Offering Amount data reported »

5-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr Note Announcement CUSIP Number data reported »

2-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
2-Yr Note Announcement Offering Amount data reported »

2-Yr Note Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

11:10
11/21/18
11/21
11:10
11/21/18
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

QQQ

Invesco QQQ Trust

$161.12

1.93 (1.21%)

11:10
11/21/18
11/21
11:10
11/21/18
11:10
Options
Notable put ratio spread opened in Invesco QQQ options as shares bounce »

Notable put ratio spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YORW

York Water

$32.80

(0.00%)

11:08
11/21/18
11/21
11:08
11/21/18
11:08
Hot Stocks
York Water raises dividend 4% to 17.33c per share »

York Water announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$65.20

0.43 (0.66%)

11:07
11/21/18
11/21
11:07
11/21/18
11:07
Periodicals
Analyst thinks Jana could pressure Exact Sciences to pursue sale, The Deal says »

Activist investor Jana…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

11:05
11/21/18
11/21
11:05
11/21/18
11:05
General news
Euro$ interest rate futures were checked lower »

Euro$ interest rate…

11:05
11/21/18
11/21
11:05
11/21/18
11:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD ticked…

DE

Deere

$143.73

5.24 (3.78%)

11:00
11/21/18
11/21
11:00
11/21/18
11:00
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere says November…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

ALT

Altimmune

$3.21

0.2 (6.64%)

10:58
11/21/18
11/21
10:58
11/21/18
10:58
Hot Stocks
Altimmune granted European patent for influenza antigen delivery vectors »

A post to the European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMX

Nymox

$1.81

0.07 (4.02%)

10:58
11/21/18
11/21
10:58
11/21/18
10:58
Hot Stocks
Nymox director James George Robinson buys 9K shares of company stock »

Nymox director James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.